Iperion posts $294,595 loss as manufacturing fees discounted and loan arranged
Iperion Limited trimmed its net loss to $294,595 for the year to March 2026, aided by waived manufacturing fees and waived licence performance targets, while securing a $250,000 loan facility to underpin ongoing development of its antimicrobial Pathoglaze product.
- Net loss reduced to $294,595 from $455,683 prior year
- No sales revenue recorded; Pathoglaze development ongoing
- $400,000 manufacturing plant fee fully discounted through 2028
- Licence performance targets permanently waived
- Secured $250,000 loan facility from related party to support working capital
Loss narrows despite zero sales as manufacturing fees waived
Iperion Limited (NZX:IPR) reported a net loss of $294,595 for the 2026 financial year, a marked improvement on the $455,683 loss recorded the previous year. This narrowing was driven primarily by a full discount on the $400,000 annual fee for its outsourced manufacturing plant, reflecting lower-than-expected production and research grant support for ongoing development of its antimicrobial product, Pathoglaze.
The company recorded no sales revenue during the year, with commercialisation efforts focused on completing development of Pathoglaze-infused polymer jute bags designed for shipping cocoa and coffee beans. This work is being conducted in collaboration with a multinational chocolate manufacturer, underscoring the product’s niche application.
Licence agreement performance targets permanently waived
A significant development came post-year-end with the permanent waiver of customer number and revenue performance targets under Iperion’s exclusive worldwide licence for Pathoglaze. These targets had stipulated minimum royalties tied to revenue milestones, which the licensor Three Summit Ventures agreed to waive in recognition of the collaborative development process and commercialisation challenges.
Additionally, Three Summit Ventures has agreed to fully discount the fixed $400,000 annual manufacturing plant fee until March 2028, providing Iperion with considerable cost relief as it continues to push towards market entry.
Loan facility and deferred fees bolster cash flow
To shore up working capital, Iperion entered a loan agreement with Elitesoft Asia, a company related to majority shareholder and director Chang Ku EE. The facility provides $250,000 at an interest rate of Hong Kong Monetary Authority Base Rate plus 4%, with potential to increase to US$1 million subject to shareholder approval. This replaces a previous $150,000 loan from Mr EE himself.
Cash reserves stood at $155,492 as at 31 March 2026, down from $425,341 the prior year. Directors have also agreed to defer 50% of their fees and 33% of management fees starting January 2026 until the company achieves positive cash flow, reflecting ongoing financial prudence.
Governance and outlook amid commercial uncertainty
Iperion’s board comprises four directors, including two independent members, maintaining compliance with NZX governance standards. The company remains in a net equity position of $53,803 but acknowledges material uncertainties regarding future sales volumes, margins, and timing of profitable operations given the novel nature of its product and market adoption hurdles.
The company’s approved base case forecasts assume no sales over the next 12 months but sufficient liquidity through the loan facility and discounted plant fees to meet obligations. However, the directors caution that unplanned costs or delayed sales could strain cash flow, underscoring the importance of monitoring commercial progress closely.
Bottom Line?
Iperion’s financial relief measures and loan facility provide a runway for Pathoglaze’s commercialisation, but the absence of sales and waived licence targets highlight ongoing execution risks.
Questions in the middle?
- When will Pathoglaze secure its first commercial sales and what scale can be expected?
- How will the company manage cash flow if sales delays extend beyond current forecasts?
- What milestones will trigger drawdowns on the expanded loan facility with Elitesoft Asia?
